This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
Two generic drug companies participated in an “at-risk” launch of generic versions of a multi-billion dollar gastroesophageal reflux drug. The generic drug companies launched “at-risk” by selling product after receiving FDA marketing approval, but while claims of patent infringement were still pending. A previous jury found that the patent-in-suit was valid and infringed, making economic damages the central remaining issue in the case.
Intensity calculated the profits that the branded drug company lost as a result of sales of generic versions of the branded drug. As part of its lost profits analysis, Intensity performed a reconstruction of a “but-for world” in which the infringement never occurred.
Reconstruction of the but-for world became an economic issue in the case due to the timing and complexity of marketplace events. The first generic company launched its product in large quantities, but stopped selling just days later. The second generic company waited to launch its generic product until the day after the branded company launched its own generic product. The first generic resumed sales of its product a number of months later. Intensity performed an analysis to quantify the economic effects of these marketplace events on lost sales and lost profits.
Our work involved quantification of the unit sales and prices that the branded company would have realized in the but-for world. The analysis included a determination of unit sales that were lost as a result of generic entry as well as additional unit sales that were made as result of the generic entry. Similarly, we performed an analysis of price erosion to determine the prices that the branded drug would have been sold at if competing generic versions had not been sold. We specifically examined the factors influencing price differences that occurred upon generic entry.
This project also involved an analysis of the economic impact of corporate structure and transfer pricing on lost profits.
Mid-Year 2025 Update: Nazaha’s Progress in the Fight Against Corruption
As part of its ongoing mandate to enhance transparency and integrity, Saudi Arabia’s Oversight and Anti-Corruption Authority (Nazaha), has continued its efforts. For the six months to June 2025, Nazaha have conducted areas of engagement into new authorities.
Justice for Players and Diarra Damages Claims
In this article, Amran Nawaz and Allan Ingraham along with Ben Cisneros and Sam Kasoulis of Morgan Sports Law discuss the JFP class action. They explore whether similar class actions could be brought by players, agents and/or clubs before the English courts, whether claims could be brought before the Court of Arbitration for Sport (CAS), and how such claims might be quantified.
Tamika Tremaglio Quoted in The Washington Post on WNBA CBA Negotiations
Managing Director Tamika Tremaglio was featured in The Washington Post discussing the WNBA’s collective bargaining negotiations and the players’ growing leverage to pursue innovative financial models, including equity stakes. She emphasized that today’s athletes better understand their value and may have access to unique alternatives if negotiations do not end the way players want.